Crossbow Therapeutics Nominates its Second Development Candidate, CBX-663, a Broadly Acting Therapeutic for a Wide Range of Solid and Hematologic Malignancies
Potent TCR-mimetic CD3 T-cell engaging antibody targets peptide HLA complexes from TERT, a broadly expressed tumor antigen
Preclinical studies demonstrate strong efficacy and a favorable safety profile
Nomination expands Crossbow’s pipeline and reinforces the scalability of its T-Bolt™ platform to treat a wide range of cancers
Excerpt from the Press Release:
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Crossbow Therapeutics, Inc., a biotechnology company developing T-Bolt™ therapies, a novel class of T-cell receptor (TCR)-mimetic antibody therapeutics, today announced the nomination of its second development candidate, CBX-663, for the treatment of a broad range of solid tumor and hematologic malignancies. The next-generation T-cell engager targets telomerase reverse transcriptase (TERT), a protein that drives tumor growth and is expressed in up to 95% of cancers.1,2
CBX-663, a bispecific antibody, binds to TERT-derived peptide human leukocyte antigen (pHLA) complexes on the surface of tumor cells and activates T-cells through a CD3-binding arm. The molecule includes two binding domains for TERT, which increase its ability to engage tumor cells and boost immune activation.
“CBX-663 illustrates how Crossbow’s TCR-mimetic platform can unlock new opportunities for antibody-based cancer therapies,” said Briggs Morrison, MD, Chief Executive Officer of Crossbow. “With strong preclinical performance selectively targeting a pHLA expressed across a broad range of cancers, CBX-663 has the potential to offer a meaningful new treatment option for patients with limited therapeutic options.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?